Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077675
Status:
COMPLETED
Last Update Posted:
2019-01-16
First Post:
2004-02-10
Brief Title:
Phase 2 Trial of TD-6424 Telavancin Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections Gram Positive cSSSI
Sponsor:
Cumberland Pharmaceuticals
Organization:
Cumberland Pharmaceuticals